hotspot -WSS

hotspot

author：knowledge 2025-09-30 00:39:54 - browse：72

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

WSS

Children’s Hospital revives plan for pedestrian bridge

Redefining sustainability for the pharmaceutical industry

Study: Black kids more likely to die after surgery than white kids

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Bird flu in dairy cattle: New measures to control spread to humans

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Republican states more likely to report Covid vaccine side effects

Malaria cases in Florida and Texas: Here’s what you need to know

Ohio train derailment: Experts on toxic chemical risks

ChatGPT in medicine: STAT answers readers' burning questions

Multiple sclerosis has subtypes with different best treatments: study

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Duchenne breakthrough therapy leaves behind pioneering families

Virtual repurposing can help discover new uses for existing drugs

focus

Pfizer is about to make a big push in cancer. Will investors listen?

Researchers test human milk's ability to repair gut microbiome

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

NEJM study measures Covid brain fog, impact on IQ

Doctor of U.S. President Joe Biden says he is fit for duty

First Opinion on colorectal cancer screening: letter and response

focus

leisure time

explore

Wikipedia